Advertisement

Topics

Mylan 2nd-qtr misses expectations; generic launches delayed

11:46 EDT 9 Aug 2017 | thePharmaLetter

Netherlands-incorporated Mylan’s (Nasdaq: MYL) shares were down 7.9% at $31.79 in pre-market trading,…

Original Article: Mylan 2nd-qtr misses expectations; generic launches delayed

NEXT ARTICLE

More From BioPortfolio on "Mylan 2nd-qtr misses expectations; generic launches delayed"

Quick Search
Advertisement